Biogen has announced it will give up ownership and halt sales of Aduhelm, an embattled Alzheimer's disease drug that was scrutinized following its 2021 approval. Biogen said it terminated a ...

Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Biogen and Eisai’s Alzheimer’s disease (AD) drug has been recommended by the European Medicines Agency’s human medicines ...

A third trial failure this year for the same experimental neurological drug has led Sage Therapeutics to discontinue ...

There are mounting concerns over Biogen’s Alzheimer’s drug aducanumab after the company announced tweaks to the design of ongoing phase 3 trials, as the FDA released new guidance designed to ...

The CMS' decision to restrict the drug came despite Biogen slashing the cost of Aduhelm in half to $28,200 a year, acknowledging that it had made a mistake in its initial pricing level. A final ...

Biogen reported third-quarter revenue and adjusted earnings that topped expectations. The company also raised its full-year profit guidance. Sales of its breakthrough Alzheimer's drug, Leqembi ...

Biogen is banking on Leqembi helping to offset the decline of its multiple sclerosis medications. Leqembi is the first drug shown to slow progression of Alzheimer’s, the mind-robbing disease ...

The European Union's drugs regulator on Thursday recommended approval of Eisai (4523.T), opens new tab and Biogen's (BIIB.O), opens new tab Leqembi for some patients with early Alzheimer's disease ...